Videos

E. Michael Lewiecki, MD, discusses the significant treatment gap seen in osteoporosis and barriers to care.

In an interview with HCPLive, E. Michael Lewiecki, MD, explores the current principles of osteoporosis treatment.

Jason Busse, DC, PhD, discusses the discrepancies and contradictions across guidelines regarding the management of chronic pain.

Jason Busse, DC, PhD, highlights the modest benefits of opioids and therapeutic cannabis in managing chronic pain.

These guidelines are designed to help clinicians incorporate the latest recommendations into their clinical practice.

S Louis Bridges Jr, MD, PhD, explores the role of artificial intelligence in managing rheumatoid arthritis.

Benjamin Smith, DMSc, PA-C, discusses integrative rheumatoid arthritis treatment guidelines.

Jinny Tavee, MD, explains the potential neurological complications of sarcoidosis, an autoimmune disease that affects multiple systems.

Tracy Frech, MD, MSCI, explains what rheumatologists need to know about preventing and management digital ischemia.

Philip J Mease, MD, highlights recent data comparing the safety and efficacy of bimekizumab with other DMARDs for the treatment of PsA.

Manuel Litchman, MD, further discusses Mustang Bio's expansion into autoimmune diseases with MB-106, an autologous CAR T-cell therapy.

Manuel Litchman, MD, discusses Mustang Bio's expansion into autoimmune diseases with MB-106, an autologous CAR T-cell therapy.

Dermatologist and rheumatologist Saakshi Khattri highlights the importance of screening psoriasis patients for psoriatic arthritis and how that may impact treatment decisions.

Judith Ng-Cashin, MD discusses Novotech's recent Rheumatoid Arthritis - Global Clinical Trial Landscape report.

John H Stone, MD, MPH, discusses the recent clinician-authored white paper from the Alliance for Patient Access: "Addressing Access Barriers for IgG4-RD Patients.”

In the final part of our 3-part series, our panel of experts discuss what their fields and its leaders could do to make sure this lack of diversity in trials does not continue. These responses are highlighted in the following video and transcribed below.

In part 2 of our 3-part series on the impact of clinical trials lacking diversity, we are spotlighting responses to our second question, which addresses how the previously established lack of diversity in clinical trials has had a direct effect on the development and application of new therapies or devices in real-world settings.

In part 1 of our 3-part series on the impact of clinical trials lacking diversity, we are spotlighting responses to our first question, which sought to encapsulate the perspectives of our group of experts on how a historic lack of diversity in clinical trials has manifested itself in today’s care of patients from diverse backgrounds.

Anisha Dua, MD, MPH, delves into recent research advancements, diagnostic hurdles, and emerging therapeutic options in vasculitis.

Anisha Dua, MD, MPH, sheds light on the intricate challenges posed by vasculitis and its mimics.

Susan Shenoi, MD, MS, previews her presentations at RWCS, discussing pivotal developments in pediatric rheumatology.

Mark Bleackley, PhD, discusses the upcoming phase 2 trial of IHL-675A designed to explore arthritis treatment through dual-drug comparison, promising global expansion, and its impact on patients’ pain relief.

Results demonstrated IHL-675A was well-tolerated, with no concerning adverse events or serious adverse events reported.

By establishing a link between endogenous retroviruses, inflammation, and autoreactive T cells in lupus, research conducted by Akiko Iwasaki, PhD, has the potential to pave the way for new targeted therapies for this complex condition.

Lora Black, PhD, sheds light on the importance of patient-centered education and comprehensive care in fibromyalgia.

Angus Worthing, MD, discusses the recent developments in rheumatology and his predictions for the future of treatment moving into 2024 and beyond.

Wesley Mizutani, MD, discusses California's SB 496 legislation, which addresses the crucial role of biomarkers in guiding optimal drug selection to improve overall healthcare outcomes.

Roger A Levy, MD, PhD, discusses the transformative impact of the KDIGO guidelines, which recommend early initiation of belimumab for lupus nephritis.

Roger A Levy, MD, PhD, discusses the recent guideline updates regarding the treatment and management of lupus nephritis.

In this discussion, experts focus on emerging treatment options for gout and share tips for monitoring and managing gout in patients with comorbid conditions.